Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CFT 8634

Next Previous
Drug Profile

CFT 8634

Alternative Names: CFT - 8634

Latest Information Update: 19 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator C4 Therapeutics
  • Class Aniline compounds; Antineoplastics; Fluorinated hydrocarbons; Piperazines; Piperidines; Pyridines; Small molecules
  • Mechanism of Action BRD9 protein degraders; Proteolysis
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours; Synovial sarcoma

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics and drug-drug interaction data from the preclinical studies in Cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 07 Jan 2024 Discontinued - Phase-I/II for Solid tumours (In adolescents, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (PO) (C4 Therapeutics pipeline; January 2023 )
  • 07 Jan 2024 Discontinued - Phase-I/II for Synovial sarcoma (In adolescents, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (PO) (C4 Therapeutics pipeline; January 2023 )

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top